Founded by a team of Italian former investment bankers, London-based activist hedge fund Bluebell Capital Partners has gained impressive momentum over the past year with its focus on listed, predominantly European large-cap companies.
The concept of outsourced trading is not new to hedge funds, but its relevance has arguably come to the fore over the last 12 months as managers of all shapes and sizes seek out ways to run their businesses as cost-effectively as possible.
Harvesting alpha: Brummer Multi-Strategy CEO Mikael Spångberg strikes optimistic tone after hedge fund soars
Brummer Multi-Strategy CEO Mikael Spångberg says the fund is in a “good position” to deliver continued positive performance, after it posted its second-best annual performance to date – but he underlined the importance of generating alpha in the face of unpredictable markets.
Hedge fund managers have experienced “significant” performance dispersion over the past 12 months, with the biggest funds seeing the largest gaps between gains and losses, new industry data shows, once again underlining the importance of investor due diligence in separating winners from losers.
As more hedge fund firms pile into the digital asset and cryptocurrency space, analysts at the London-listed hedge fund giant Man Group say bitcoin’s recent volatility could be seen as “price discovery” in a new asset class, which will ultimately give way to greater stability in the currency, and more credibility among investors.
Hedge fund strategies soar: Industry enjoys biggest annual return since Global Financial Crisis, as managers weather 2020 storm with double-digit surge
Hedge funds weathered the political, social and economic shocks brought about by the global pandemic and frequent bursts of soaring volatility to score a near-12 per cent return last year – their best since 2009 – outperforming both the Dow Jones Industrial Average and FTSE 100, new data from Hedge Fund Research shows.
Founded in 2005, EJF Capital focuses on investment opportunities in financial services, targeting all levels of the capital structure on both a long-only and long/short basis. Specifically, the firm’s strategy seeks out ideas stemming from regulatory and structural changes impacting the banking sector, insurance companies and specialty finance.
All eyes will be on the European Commission’s legal proposal pertaining to the AIFM Directive, which is expected to be published sometime in the first half of 2021, and could usher in an updated version – AIFMD II – a decade after it was first adopted.
Former Grosvenor executive prepares to roll out multi-strategy digital asset fund – Dalpha Capital Management
With bitcoin hitting the headlines in recent weeks, reaching an all-time high of USD19,915 on 1 December, investors have been keen to pile in. Even the likes of Bridgewater’s Ray Dalio and Paul Tudor Jones are coming around to the fact that there could be something happening with bitcoin, having made a Lazarus-like recovery since its price tanked close to USD3,000 in December 2018.
Hedge fund returns for 2021 are forecast to be lower due to lower public market performance, but despite this improved operating conditions should be supportive for most hedge fund strategies to generate alpha.
“Digital gold”: As bitcoin soars to record highs, hedge funds are capitalising on 2020’s crypto boom
When bitcoin hit an all-time high of some USD20,000 earlier this month, it rounded off a remarkable year for the world’s leading cryptocurrency – and fully underlined the arrival of the once-niche asset class on a rapidly-growing number of hedge fund firms’ radars.
Cocktail parties, oil markets, and why China resembles Bismarck’s Germany as it continues to exert its economic influence – in conversation with Massar Capital’s Marwan Younes…
This year’s Covid-19 stock market upheaval has revealed an “Achilles’ heel” in quantitative hedge fund models that use traditional factors such as momentum and value, as machine-based strategies have struggled against “unique new drivers of stock returns that don’t fit the academic models”, says Man FRM.
Total global hedge fund assets under management have mushroomed to a record USD3.6 trillion, thanks to defensive outperformance and opportunistic gains during 2020’s upheaval – though the biggest firms continue to take the lion’s share of investor capital as smaller names are squeezed.
JP Morgan Asset Management forecasts “rich environment” for hedge funds as ‘megatrends’ take centre-stage
The fallout from the coronavirus pandemic is set to unlock global “megatrends” this year, including consumer and corporate technology, healthcare, and sustainability themes – and hedge fund investors can expect a “rich environment for growth”, a major new study by JP Morgan Asset Management suggests.
As more hedge funds pile into cryptocurrencies, market inefficiencies and price dispersion are bringing fresh arbitrage opportunities for managers.
In the third in a four-part series from the DMS Client Solutions Team exploring the challenges and opportunities presented by the shifting European regulatory landscape, David Morrissey, DMS Global Head of Client Solutions offers his unique personal perspective on the evolution of the third party management company sector.
Amsterdam-headquartered Privium Fund Management and London-based software provider Swarm Technology have paired up to launch Swarm XVI, a novel managed futures programme whose trading technology and quantitative investment processes mimic behaviours seen in insect colonies.
Rhenman & Partners Asset Management says it is closing its Rhenman Global Opportunities L/S strategy and intends to return capital back to investors.
2020 has been a reminder that unforeseen circumstances can cause even the most stable of investment environments to switch quickly into being unpredictable and volatile.
UK hedge fund Argonaut takes aim at AstraZeneca-Oxford vaccine and warns against “silver bullet” recovery
The recent stock market “exuberance” sparked off by breakthroughs in Covid-19 vaccine trials may give way to disappointment next year, says Argonaut Capital CEO and CIO Barry Norris, who continues to build short positions in a number of drug companies, including AstraZeneca, amid continued uncertainty over efficacy and dosage in its trial process.